文献速递消化道肿瘤放疗

基线肌少症对D2胃癌辅助治疗的影响:ARTIST III期试验分析

Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial.
PubMed 文献 · Radiother Oncol · 2020-07-31

该研究基于ARTIST III期试验中D2根治术后胃癌患者,评估术前肌少症对辅助放化疗(XP-RT)与单纯化疗(XP)疗效的影响。440例可评估患者中75例(17.0%)存在术前肌少症。在无术前肌少症亚组中,XP-RT组复发显著低于XP组(p=0.02),无复发生存(RFS)显著更高(p=0.02,HR 0.633,95%CI 0.433-0.926),多因素分析后仍维持。

要点

  • 术前肌少症发生率为17.0%(75/440例)。
  • 有无肌少症者治疗相关毒性和依从性无差异。
  • 仅无肌少症者中XP-RT较XP显著改善RFS。

核心结论

  • 辅助XP-RT优于XP的临床获益仅在无术前肌少症的D2胃癌患者中观察到。

研究设计与样本

  • 基于ARTIST III期试验队列的二次分析,纳入D2根治术后胃癌患者,用验证软件测量术前CT L3骨骼肌指数(SMI),按韩国特异性 cutoff 定义肌少症(男≤49 cm2/m2,女≤31 cm2/m2),共440例可评估。

主要发现

  • 440例中75例(17.0%)符合术前肌少症定义。
  • 两个治疗组中,有无术前肌少症者的治疗相关毒性或治疗依从性均无差异。
  • 无术前肌少症亚组中,XP-RT组复发显著低于XP组(p=0.02)。
  • 无术前肌少症亚组中,XP-RT组RFS显著更高(p=0.02,HR 0.633,95%CI 0.433-0.926)。
  • 多因素校正显著预后因素后,无术前肌少症亚组中XP-RT的RFS优势仍维持。

关键数值与推荐

  • 肌少症定义:L3 SMI≤49 cm2/m2(男)或≤31 cm2/m2(女)。
  • 无术前肌少症亚组中XP-RT vs XP的RFS:HR 0.633(95%CI 0.433-0.926),p=0.02。

临床怎么用

  • 对D2胃癌术后拟行辅助治疗者,可评估术前L3 SMI;无肌少症者选择XP-RT可能获益更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study evaluated the clinical significance of preoperative sarcopenia according to adjuvant concurrent chemo-radiotherapy (XP-RT) or chemotherapy alone (XP) in the D2 dissected gastric cancer patient cohort of the ARTIST trial. MATERIALS AND METHODS: Skeletal muscles at the L3 vertebra level from preoperative computed tomography images among the ARTIST trial participants were measured using validated in-house software. Skeletal muscle index (SMI) was defined as the measured skeletal muscle area divided by the square of the height, and sarcopenia was defined according to the Korean-specific cutoff, i.e. L3 SMI ≤ 49 cm2/m2 for men and ≤31 cm2/m2 for women. RESULTS: Among the 440 patients in whom we were able to evaluate L3 SMI, 75 (17.0%) met the definition for preoperative sarcopenia. No differences in treatment-related toxicities or treatment compliance were observed according to the presence of preoperative sarcopenia in either treatment arm. In the subgroup of patients without preoperative sarcopenia, recurrence was significantly lower in the XP-RT arm than that in the XP arm (p = 0.02). Recurrence-free survival (RFS) was also significantly higher in the XP-RT arm (p = 0.02, hazard ratio 0.633, 95% confidence interval 0.433-0.926) in this subgroup. In the multivariate analysis, and after adjusting for significant prognostic factors, the superior outcome of XP-RT arm regarding RFS was maintained in the subgroup of the patients without preoperative sarcopenia. CONCLUSIONS: Superior clinical outcomes of adjuvant XP-RT over XP were only observed in patients without preoperative sarcopenia.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yu JI, Choi C, Lee J, et al. Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiother Oncol. 2020. PMID: 32739319. doi:10.1016/j.radonc.2020.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。